Year |
Citation |
Score |
2023 |
Jiang Y, Aireti M, Leng X, Ji X, Liu J, Cui X, Duan H, Jing Q, Cao H. Structures, Electronic, and Magnetic Properties of CoK ( = 2-12) Clusters: A Particle Swarm Optimization Prediction Jointed with First-Principles Investigation. Nanomaterials (Basel, Switzerland). 13. PMID 37570473 DOI: 10.3390/nano13152155 |
0.404 |
|
2020 |
Chen C, Cheng CD, Wu H, Wang ZW, Wang L, Jiang ZR, Wang AL, Hu C, Dong YF, Niu WX, Qi S, Qi ZP, Liu J, Wang WC, Niu CS, et al. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. Acta Pharmacologica Sinica. PMID 32398685 DOI: 10.1038/S41401-020-0418-2 |
0.304 |
|
2018 |
Liu X, Wang B, Chen C, Jiang Z, Hu C, Wu H, Zhang Y, Liu X, Wang W, Wang J, Hu Z, Wang A, Huang T, Liu Q, Wang W, ... ... Liu J, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. European Journal of Medicinal Chemistry. 160: 61-81. PMID 30317026 DOI: 10.1016/J.Ejmech.2018.10.007 |
0.312 |
|
2018 |
Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, ... ... Liu J, et al. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. European Journal of Medicinal Chemistry. 158: 896-916. PMID 30253346 DOI: 10.1016/J.Ejmech.2018.09.025 |
0.312 |
|
2017 |
Liang Q, Chen Y, Yu K, Chen C, Zhang S, Wang A, Wang W, Wu H, Liu X, Wang B, Wang L, Hu Z, Wang W, Ren T, Zhang S, ... ... Liu J, et al. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. European Journal of Medicinal Chemistry. 131: 107-125. PMID 28315597 DOI: 10.1016/J.Ejmech.2017.03.001 |
0.313 |
|
2016 |
Wang Q, Liu F, Wang B, Zou F, Qi Z, Chen C, Yu K, Hu C, Qi S, Wang W, Hu Z, Liu J, Wang W, Wang L, Liang Q, ... ... Liu J, et al. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. Journal of Medicinal Chemistry. PMID 27966954 DOI: 10.1021/Acs.Jmedchem.6B01290 |
0.315 |
|
2016 |
Liu F, Wang B, Wang Q, Qi Z, Chen C, Kong LL, Chen JY, Liu X, Wang A, Hu C, Wang W, Wang H, Wu F, Ruan Y, Qi S, ... Liu J, ... ... Liu J, et al. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget. PMID 27322145 DOI: 10.18632/Oncotarget.10037 |
0.301 |
|
2016 |
Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W, Zhao Z, Wang A, Chen YF, Wang L, Gray NS, ... Liu J, et al. Discovery of a Highly Selective STK16 Kinase Inhibitor. Acs Chemical Biology. PMID 27082499 DOI: 10.1021/Acschembio.6B00250 |
0.313 |
|
2016 |
Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, ... ... Liu J, et al. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. PMID 27081697 DOI: 10.18632/Oncotarget.8702 |
0.307 |
|
2016 |
Wang Q, Liu F, Wang B, Zou F, Chen C, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, ... ... Liu J, et al. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). Journal of Medicinal Chemistry. PMID 27077705 DOI: 10.1021/Acs.Jmedchem.6B00200 |
0.312 |
|
2015 |
Li X, Wang A, Yu K, Qi Z, Chen C, Wang W, Hu C, Wu H, Wu J, Zhao Z, Liu J, Zou F, Wang L, Wang B, Wang W, ... ... Liu J, et al. Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. Journal of Medicinal Chemistry. PMID 26630553 DOI: 10.1021/Acs.Jmedchem.5B01611 |
0.325 |
|
2015 |
Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, ... ... Liu J, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. PMID 26165234 DOI: 10.1038/Leu.2015.180 |
0.321 |
|
2014 |
Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, ... ... Liu J, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. Acs Chemical Biology. 9: 1086-91. PMID 24556163 DOI: 10.1021/Cb4008524 |
0.316 |
|
2012 |
Liu J, Hu Y, Waller DL, Wang J, Liu Q. Natural products as kinase inhibitors. Natural Product Reports. 29: 392-403. PMID 22231144 DOI: 10.1039/C2Np00097K |
0.3 |
|
2011 |
Ko E, Liu J, Burgess K. Minimalist and universal peptidomimetics. Chemical Society Reviews. 40: 4411-21. PMID 21483946 DOI: 10.1039/C0Cs00218F |
0.565 |
|
2011 |
Ko E, Liu J, Perez LM, Lu G, Schaefer A, Burgess K. Universal peptidomimetics. Journal of the American Chemical Society. 133: 462-77. PMID 21182254 DOI: 10.1021/ja1071916 |
0.552 |
|
2010 |
Brahimi F, Liu J, Malakhov A, Chowdhury S, Purisima EO, Ivanisevic L, Caron A, Burgess K, Saragovi HU. A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist. Biochimica Et Biophysica Acta. 1800: 1018-26. PMID 20600627 DOI: 10.1016/J.Bbagen.2010.06.007 |
0.458 |
|
2010 |
Bai Y, Shi Z, Zhuo Y, Liu J, Malakhov A, Ko E, Burgess K, Schaefer H, Esteban PF, Tessarollo L, Saragovi HU. In glaucoma the upregulated truncated TrkC.T1 receptor isoform in glia causes increased TNF-alpha production, leading to retinal ganglion cell death. Investigative Ophthalmology & Visual Science. 51: 6639-51. PMID 20574020 DOI: 10.1167/Iovs.10-5431 |
0.514 |
|
2010 |
Liu J, Brahimi F, Saragovi HU, Burgess K. Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists. Journal of Medicinal Chemistry. 53: 5044-8. PMID 20540510 DOI: 10.1021/Jm100148D |
0.458 |
|
Show low-probability matches. |